No Data
No Data
Express News | Watching Regulus Therapeutics; Shares See Volume To The Upside As Traders Circulate TipRanks Article Titled 'These 2 'Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts'
Ventyx Biosciences' Tamuzimod: Promising Data but Insufficient for Upgrade Beyond Hold
Express News | Ventyx Biosciences Presents New 52-Week Results From the Phase 2 Trial of Vtx002 (Tamuzimod) in Ulcerative Colitis at Ueg Week 2024
Ventyx Biosciences Presents New 52-Week Results From the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Maintains Target Price $10
LifeSci Capital Maintains Ventyx Biosciences(VTYX.US) With Buy Rating
No Data
No Data